Kopran Ltd

KOPRAN NSE Healthcare Pharmaceuticals
₹235.26
-0.24%
Delayed · cached 15 min

Fair value analysis

KOPRAN
Kopran Ltd
HealthcarePharmaceuticals
₹235.82
Close used for this calculation
₹134.20Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
28/100
Profitability4/25
Returns1/25
Balance Sheet16/25
Efficiency7/25
Growth3/25
Weak
Quality radar
28Prof.4/25Ret.1/25Eff.7/25B.Sht16/25Growth3/25

Consensus fair value

₹134.20
Above FV
▼ -43.1% against the close used
Model range ₹29.25 – ₹190.28
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹29.25Fair value₹134.20Bull₹190.28
FairClose
52-week traded range
52W low ₹108.0452W high ₹239.51

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Kopran Ltd closed at ₹235.82, 75.7% above the consensus fair value of ₹134.20 drawn from 8 valuation models.

Financial DNA score 28/100 — Weak. P/E of 45.5x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹99.90
-57.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹113.38
-51.9%
√(22.5 × EPS × BVPS)
EPS=5.33, BVPS=107.19 · outside Graham range (P/E 45.5, P/B 2.2) — asset-light, treat as a rough floor
P/E Fair Value
₹190.28
-19.3%
EPS × 35.7x (sector P/E)
EPS=5.33, Sector P/E=35.7x
EV/EBITDA
₹132.23
-43.9%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=790M
Dividend Discount (DDM)
₹38.49
-83.7%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=3.02, r=10%, g=2%
Book Value (P/B)
₹29.25
-87.6%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=107.19, ROE=4.9%, g=3%, r=10%
Reverse DCF
₹235.82
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 17.9% | Historical: 0%
Margin of Safety
₹100.89
-57.2%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=134.52, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.